Welcome to our dedicated page for Cvs Health news (Ticker: CVS), a resource for investors and traders seeking the latest updates and insights on Cvs Health stock.
CVS Health Corporation operates an integrated health care model that combines retail pharmacy, pharmacy benefit management, health insurance, medical clinics, specialty and mail pharmacy support, and related consumer health services. Recurring company news includes quarterly results and guidance, segment performance across Health Services, Health Care Benefits, and Pharmacy & Consumer Wellness, and capital returns through common-stock dividends.
Updates also cover CVS Caremark formulary decisions, biosimilar adoption, Aetna prior authorization and plan-administration initiatives, community health investments by the CVS Health Foundation, and developments involving Omnicare, the company's long-term care pharmacy subsidiary.
CVS Health (NYSE: CVS) will hold its second quarter 2026 earnings conference call with analysts and investors on Wednesday, August 5, 2026, at 8:00 a.m. ET.
An audio webcast will be available live and archived for one year at investors.cvshealth.com.
CVS (NYSE:CVS), through the CVS Health Foundation, is awarding $1 million in Hometown Fund grants to 20 nonprofits in Greater Hartford. Funding targets access to health care, food security, stable housing and essential community services.
In 2025, CVS Health and its foundation contributed $2.61 million in charitable giving across Connecticut.
CVS (CVS), through the CVS Health Foundation, is investing $1 million via its Hometown Fund in 20 Rhode Island nonprofits.
Grants support access to health care, food, stable housing and essential services, and follow more than $2.64 million in 2025 charitable giving and other community investments in Rhode Island.
CVS (NYSE: CVS) announced expanded GLP‑1 support across more than 9,000 CVS Pharmacy locations and MinuteClinic virtual care nationwide. The initiative combines lower-cost access, pharmacist guidance, and over-the-counter products to help patients start and stay on GLP‑1 therapy.
Key elements include CVS participation in the CMS Medicare GLP‑1 Bridge program from July 1, 2026, through December 31, 2027, offering eligible Medicare patients select GLP‑1 medications for $50 monthly copays. For commercially insured patients, out-of-pocket costs can be as low as $25 per month with manufacturer coupons, or $149 per month for certain uninsured patients using manufacturer vouchers.
MinuteClinic is launching a new virtual weight management program with $49 self-pay visits, available in 47 states and Washington, D.C., for adults ages 18‑64. Licensed clinicians can assess metabolic health and, when clinically appropriate, prescribe FDA-approved GLP‑1 medications for weight loss with follow-up support.
AM Best affirmed the FSR of A (Excellent) and Long-Term ICR of “a” (Excellent) for Aetna Life Insurance Company, other Aetna Health & Life Group members, Allina Health and Aetna Insurance Company, and CVS Caremark Indemnity, all with stable outlooks.
Affirmations reflect very strong balance sheet strength at Aetna Health & Life Group, improved 2025 earnings after 2024 underwriting losses, stronger Medicare Advantage Star Ratings, and continued support from parent CVS Health (NYSE: CVS), partly offset by elevated CVS financial leverage and high goodwill and intangibles.
CVS Health (NYSE: CVS) received the 2026 Newsweek AI Impact Award in the AI Health Care category for Best Outcomes – Patient Care. The honor recognizes CVS Health's AI-Driven Prescription Interpretation and Instruction Standardization technology embedded in pharmacy dispensing workflows.
The AI uses trained open-source large language models to interpret complex prescription directions and calculate precise dosage supply, helping reduce manual transcription, speed retail prescription fulfillment, and accelerate specialty pharmacy onboarding while keeping pharmacists in final clinical control.
Aetna, a CVS Health company (NYSE: CVS) introduced Aetna Mental Health On Demand, offering real-time access to licensed clinicians via chat, phone or video for members aged 13 and older. The service uses a single-session intervention model, AI-powered tools, and predictive analytics, and is slated for self-insured customers starting January 1, 2027.
During the initial launch, clinicians responded to members in about 13 seconds, aiming to improve access, support care coordination, and reduce avoidable hospitalizations through proactive outreach.
ARCTRUST Private Capital acquired a seven-property, single-tenant net lease portfolio for its planned ARCTRUST Exchange II DST, targeting 1031 exchange investors.
The portfolio totals about 51,192 square feet on 7.75 acres, spans six states, has a 13.6-year weighted average lease term, and features absolute triple-net leases with CVS Pharmacy (NYSE: CVS), Pinnacle Bank, and NAPA Auto Parts–branded locations.
Salesforce (NYSE: CRM) and CVS Health are expanding their decade-long collaboration to enhance call center care using Agentforce Health, Salesforce's AI-powered health solution.
The platform will support Aetna and CVS Caremark, serving millions of members and 1.5 million providers with faster, more personalized, data-driven interactions.
CVS Health (NYSE: CVS) is expanding GLP-1 weight management coverage through CVS Caremark’s commercial formularies. Zepbound (tirzepatide) will be reintroduced as an additional preferred option on October 1, 2026, and the new-to-market block on oral GLP-1 Foundayo (orforglipron) ends June 1, 2026, where plans approve coverage.
According to CVS Health, these formulary updates aim to improve affordability and access for plan sponsors and members via manufacturer negotiations, while maintaining plan flexibility and providing education and clinical support for smooth transitions.